How the Omnipod® 5 System
Successful management of type 1 diabetes (T1D) requires ongoing effort, attention and time which can impact every aspect of patients’ day-to-day lives. Omnipod® 5 with SmartAdjustTM technology is an Automated Insulin Delivery system consisting of an on-body Pod communicating directly with a compatible sensor that has been demonstrated to improve glycaemic control and quality of life.1-3
The majority of patients with T1D do not meet their glycaemic targets4
90% of adults and 88% of children and young people in England and Wales are not meeting the HbA1c target of 6.5% (48 mol/mol).5,6
How can you help simplify your patients’ T1D management?
Omnipod® 5 significantly improved HbA1c and time in range (TIR) in users from 2 years of age in pivotal trials*†1,2
Omnipod® 5 reduced HbA1c by 0.5% in very young children and 53% of children and 66% of adults/adolescents had an HbA1c of less than 7%.*†1,2
Description of studies
However, HbA1c is not the only measure of glycaemic control. TIR was also significantly improved with Omnipod® 5 (p<0.0001).‡1,2
† Vs baseline (MDI or CSII, HbA1c only) or standard therapy (MDI or CSII, other outcomes).
‡ p<0.0001 vs standard therapy (MDI or CSII).
Description of studies
Omnipod® 5 significantly reduced hyperglycaemia in users from 2 years of age and hypoglycaemia in adults/adolescents*†1,2
Omnipod® 5 significantly reduced time in hyperglycaemia in users from 2 years of age (p<0.0001).†1,2 Time in hypoglycaemia was significantly reduced in adults and adolescents (p<0.0001), while remaining low in children.1,2
Overnight hypoglycaemia was significantly reduced in very young children and adults/adolescents.‡
† Vs baseline (MDI or CSII, HbA1c only) or standard therapy (MDI or CSII, other outcomes).
‡ Overnight defined as midnight to 6 AM.
Low rates of diabetic ketoacidosis (DKA) and severe hypoglycaemia were reported with Omnipod® 5 use1,2
-
The incidence rate of DKA during the AID phase was 1.2 events per 100 person-years among children aged 6 years and over, adolescents and adults
-
There were no episodes of DKA or severe hypoglycaemia among very young children
- The incidence rate of severe hypoglycaemia during the AID phase was 4.8 events per 100 person-years in children aged over 6 years and adults/adolescents
Description of studies
Both the efficacy and simplicity of use of Omnipod® 5 are reflected by the high proportion of study time in which users stayed in automated mode (>95% across all age groups):*1,2
Description of studies
See the Omnipod® 5 data
As well as demonstrating improvements in glycaemic control, Omnipod® 5 has also been shown to deliver improvements in patient reported outcomes.3
Contact our Medical Affairs or Medical Information teams
At Insulet, our aim is to keep on improving the lives of those living with T1D. With this in mind we aim to generate real-world data to provide further evidence on the efficacy of Pod Therapy. If you want to know more about our current trials and development pipeline do not hesitate to contact our Medical Affairs team at [email protected] or our Medical Information team at [email protected].
Arrange a meeting with an Omnipod® representative
Do you have questions about the Omnipod DASH® System? Our team is on call to provide you with the information you need and help you to determine which of your patients could best benefit from the Omnipod DASH® System.
Be the first to know
Stay up to date and be in the know when it comes to all things Insulet. By signing up for our mailing list, you will be in the know when it comes to training and events, Omnipod® published data and first-hand experiences from Podders®.
NDA-TYPE1-REP-v20220615_FINAL.pdf [Accessed June 2023]. 6. National Paediatric Diabetes Audit 2020/2021. England and Wales. Available at: https://www.rcpch.ac.uk/sites/default/files/2022-04/NPDA%20report%202020-21%20Appendix%201%20Full%20audit%20analysis_0.pdf [Accessed June 2023].